OSE Immunotherapeutics Receives €8.4 M in Public Funding to Support the Registration Phase 3 Clinical Trial of Cancer Vaccine Tedopi® in Lung Cancer
GlobeNewswire
*OSE Immunotherapeutics Receives €8.4 M in Public Funding *
*to Support the Registration Phase 3 Clinical Trial *
*of..